

THE LANCET

Child & Adolescent Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Issitt RW, Booth J, Bryant WA, et al. Children with COVID-19 at a specialist centre: initial experience and outcome. *Lancet Child Adolesc Health* 2020; published online June 22. [http://dx.doi.org/10.1016/S2352-4642\(20\)30204-2](http://dx.doi.org/10.1016/S2352-4642(20)30204-2).

Table. Patient demographic data, proportion in vulnerable groups, outcome and laboratory features of 65 CoVPos patients presenting to a specialist children’s hospital with COVID-19 disease. (Median [interquartile range] and N (%))

	COVID–19 Positive
Number of Patients	65 (38·7)
Male	38 (58·5)
Female	27 (41·5)
Age (Years)	9 [0·9 - 14]
Vulnerable*	31 (47·7)
1 (National) Transplant	1 (3·2)
1d (National) Transplant Medication	1 (3·2)
2a (National) Cancer undergoing active chemo/radiotherapy	7 (22·6)
2b (National) Haematological Cancers	2 (6·4)
3 (National) Respiratory	1 (3·2)
4 (National) Rare genetic, metabolic and autoimmune diseases	5 (16·2)
C (Local) People with severe respiratory conditions	5 (16·2)
D (Local) People with rare diseases	1 (3·2)
E (Local) People on immunosuppression therapies	1 (3·2)
O (Local) Other potential factors	7 (22·6)
Mortality	1 (1·5)**

Mortality in Vulnerable	1 (1·5)
Mortality in Non-Vulnerable	0
Ethnicity	
Asian	12 (18·5)
Black African	6 (9·2)
Other	3 (4·6)
Unrecorded/Refused	31 (47·7)
White	13 (20)
Alanine Transaminase (U/L)	41·5 [29 – 74]
Albumin (g/L)	32 [27 – 36]
AntiDNAase B (U/mL)	310 [80·8 – 402]
AntiStreptolysin O (IU/mL)	285 [134 – 384]
Aspartate Transaminase (U/L)	70 [43 – 100]
C-Reactive Protein (mg/L)	28 [10 – 74]
Creatine Kinase (U/L)	63·5 [35 – 214]
Creatinine (µmol/L)	23 [14 – 46]
D-Dimers (µg/L)	1876 [1043 – 3618]
Ferritin (µg/L)	788 [445 – 1863]
Fibrinogen (g/L)	3·65 [2·4 – 4·8]
Interleukin-6 (pg/mL)	50 [50 – 152]
Interleukin-10 (pg/mL)	50 [50 – 50]
Lactate Dehydrogenase (U/L)	848 [654 – 1136]
Lymphocytes (x10⁹/L)	1·44 [0·64 – 2·49]
Neutrophils (x10⁹/L)	3·90 [1·46 – 8·60]

NT-pro-Brain Natriuretic Peptide (pg/mL)	3550 [626 – 6992]
Prothrombin time (seconds)	12 [11.3 – 13]
Total bilirubin (µmol/L)	6 [3 – 10]
Triglycerides (mmol/L)	2.48 [1.65 – 3.56]
Troponin I (ng/L)	54 [13 – 157]
Urine Total Protein (g/L)	0.12 [0.12 – 0.62]
White Blood Cells (x10⁹/L)	8 [3.38 – 13.2]

*Based on UK guidance for vulnerable groups⁴

**The death in this group occurred in a child with proven SARS-CoV-2 infection but was related to pre-existing underlying conditions and associated coinfection.

Figure 1: Presentations to a specialist children’s hospital of children with COVID-19 infection by vulnerability status.




Figure 2: Vulnerability groups for admissions of 65 paediatric patients symptomatic with suspected COVID-19 disease.

